1,052,509 Halozyme Therapeutics, Inc. $HALO Shares Acquired by Congress Asset Management Co.

by · The Markets Daily

Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 85.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,281,615 shares of the biopharmaceutical company’s stock after buying an additional 1,052,509 shares during the period. Halozyme Therapeutics comprises approximately 1.6% of Congress Asset Management Co.’s portfolio, making the stock its 7th largest position. Congress Asset Management Co.’s holdings in Halozyme Therapeutics were worth $251,890,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Twin Capital Management Inc. raised its stake in shares of Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 161 shares during the last quarter. First Citizens Bank & Trust Co. grew its stake in shares of Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 175 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its holdings in Halozyme Therapeutics by 1.2% in the first quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock valued at $981,000 after purchasing an additional 183 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Halozyme Therapeutics by 0.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 202 shares during the period. Finally, Tema ETFs LLC grew its position in shares of Halozyme Therapeutics by 0.6% in the 2nd quarter. Tema ETFs LLC now owns 32,598 shares of the biopharmaceutical company’s stock valued at $2,551,000 after buying an additional 210 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 1.3%

NASDAQ HALO traded up $1.41 during trading hours on Tuesday, hitting $109.72. 1,774,255 shares of the company’s stock were exchanged, compared to its average volume of 1,930,240. The firm has a market cap of $12.45 billion, a price-to-earnings ratio of 32.75, a PEG ratio of 0.42 and a beta of 0.88. The stock has a 50-day simple moving average of $104.03 and a 200 day simple moving average of $81.87. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $116.85.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 87,775 shares of company stock valued at $9,311,844 over the last ninety days. 2.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $91.20.

View Our Latest Analysis on Halozyme Therapeutics

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).